Distribution of non-O1 <i>Vibrio cholerae</i> infections by month.

<p>Distribution of non-O1 <i>Vibrio cholerae</i> infections by month.</p

Comparison between patients with survival and mortality.

<p>Comparison between patients with survival and mortality.</p

Prognostic factors associated with in-hospital mortality.

<p>Prognostic factors associated with in-hospital mortality.</p

Clinical characteristics of 91 patients with bacteremia caused by <i>Aeromonas</i> species.

<p>Clinical characteristics of 91 patients with bacteremia caused by <i>Aeromonas</i> species.</p

Demographic characteristic of 83 patients with non-O1 <i>Vibrio cholerae</i> infections.

<p>*Significant difference between acute gastroenteritis and biliary tract infection</p><p>^† Significant difference between acute gastroenteritis and primary bacteremia</p><p>^＃Significant difference between biliary tract infection and primary bacteremia</p><p>Demographic characteristic of 83 patients with non-O1 <i>Vibrio cholerae</i> infections.</p

Rates of <i>Aeromonas</i> species that were not susceptible to 12 antimicrobial agents by the disk diffusion method.

<p>Rates of <i>Aeromonas</i> species that were not susceptible to 12 antimicrobial agents by the disk diffusion method.</p

Comparison of 43 patients and 48 patients with healthcare-associated and community-acquired bacteremia caused by <i>Aeromonas</i> species.

<p>Comparison of 43 patients and 48 patients with healthcare-associated and community-acquired bacteremia caused by <i>Aeromonas</i> species.</p

sj-pdf-1-sci-10.1177_00368504241231154 - Supplemental material for Mesenchymal stem cells reduce long-term cognitive deficits and attenuate myelin disintegration and microglia activation following repetitive traumatic brain injury

Supplemental material, sj-pdf-1-sci-10.1177_00368504241231154 for Mesenchymal stem cells reduce long-term cognitive deficits and attenuate myelin disintegration and microglia activation following repetitive traumatic brain injury by Lan-Wan Wang, Chung-Ching Chio, Chien-Ming Chao, Pi-Yu Chao and Mao-Tsun Lin, Ching-Ping Chang, Hung-Jung Lin in Science Progress</p

Demography of patients.

<p>*Only 75 patients followed up one year after surgery</p><p>Demography of patients.</p

Clinical Experience of Patients Receiving Doripenem-Containing Regimens for the Treatment of Healthcare-Associated Infections

<div><p>In this study, we retrospectively reviewed the clinical experience of patients receiving doripenem-containing regimens for the treatment of healthcare-associated infections (HCAIs) in a tertiary care center and assessed the clinical usefulness of doripenem therapy in this clinical setting. In this retrospective study, the medical records of all adult patients who had ever received doripenem-containing therapy for the treatment of HCAIs were reviewed between September 1, 2012 and August 31, 2014, and the following data were extracted: age, gender, type of infection, disease severity, underlying comorbidities or conditions, and laboratory results. Additionally, we also extracted data regarding the rates of mortality and clinical and microbiological response. A total of 184 adult patients with HCAIs who had received doripenem-containing therapy were included in this study. Respiratory tract infections (n = 91, 49.5%) were the most common type of infection, followed by urinary tract infections, intra-abdominal infections and skin and soft tissue infections. The mean APACHE II score was 14.5. The rate of clinical success was 78.2%, and the overall in-hospital mortality rate was only 13.0%. Among patients, in-hospital mortality was independently and significantly associated with APACHE II score (odds ratio (OR), 1.2825; 95% CI, 1.1123–1.4788) and achieving clinical success (OR, 0.003; 95% CI, 0.0003–0.409). In conclusion, the overall in-hospital mortality rate was low and the clinical success rate was high among HCAI patients receiving doripenem treatment. These results suggest that doripenem may be judiciously used for the treatment of patients with HCAIs.</p></div